Low-secretory multiple myeloma

Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.

Show simple item record

dc.contributor.author Visser, Hilgaard Frans
dc.contributor.author Visser, Adele
dc.contributor.author Nel, J.M.
dc.contributor.author Moodley, Vanessa
dc.contributor.author Swart, Andre
dc.contributor.author Pool, Roger
dc.date.accessioned 2010-04-15T09:08:28Z
dc.date.available 2010-04-15T09:08:28Z
dc.date.issued 2009
dc.description.abstract Multiple myeloma (MM) is an incurable malignancy arising from postgerminal B lymphocytes. It is estimated to account for 10-15% of haematological malignancies and 1% of all malignancies. Non-secretory multiple myeloma (NSMM) is a rare variant of MM, where no monoclonal immunoglobulin (M-protein) can be demonstrated in either the urine or serum. NSMM is estimated to occur in 1-5% of all myeloma cases. So-called 'low-secretory' forms also exist, where the degree of immunoglobulin production does not fulfil the diagnostic criteria, but monoclonal production does occur. The lack of M-protein in NSMM may be due to the inability of the plasma cell to excrete the immunoglobulin, an inherent low synthetic capacity, or intra- or extra-cellular degradation of the M-protein upon production. Patients typically present with fatigue, bone pain and recurrent infections. Bone involvement is common in this disorder with an estimated 80% of patients having radiographic abnormalities upon diagnosis. The majority present with focal lytic lesions (~60%), with osteoporosis (~20%), pathological fractures (~20%) and spinal compression fractures (~20%) seen in the remainder. Metastatic disease is a significant contributor to patient morbidity, since it significantly affects the patient's ability to perform activities of daily living. The humerus is the second-most common site affected after the femur. Surgical intervention is aimed at providing pain relief and restoration of limb function, and is usually not indicated in patients with a very short life expectancy, but this practice remains controversial. In this report we describe a patient with a low-secreting myeloma, presenting with a pathological fracture, in which establishment of the diagnosis according to the World Health Organization (WHO) criteria required crative sampling. en_US
dc.identifier.citation Visser, HF, Visser, A, Nel, JM, Moodley, V, Swart, A & Pool, R (2009), 'Low-secretory multiple myeloma', SA Orthopaedic Journal, vol. 8, no. 4, pp. 76-80. [http://www.charpublications.co.za/C_JournalsORTH.asp] en_US
dc.identifier.issn 1681-150X
dc.identifier.uri http://hdl.handle.net/2263/13953
dc.language.iso en en_US
dc.publisher South African Orthopaedic Association / Char Publications en_US
dc.rights South African Orthopaedic Association / Char Publications en_US
dc.subject Multiple myeloma en_US
dc.subject Low-secretory en_US
dc.subject Non-secretory multiple myeloma en_US
dc.subject NSMM en_US
dc.title Low-secretory multiple myeloma en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record